733805-92-0

Orniplabin, also known as SMTP-7 is a dual inhibitor of thrombolysis and soluble epoxide hydrolase. SMTP-7 promotes thrombolysis and inhibits soluble epoxide hydrolase.

Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS[1][2].

[1] Shibata K, et al. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382(3):245-53. DOI:10.1007/s00210-010-0542-5
[2] Shibata K, et al. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384(1):103-8. DOI:10.1007/s00210-011-0642-x